ArticleCancer letters2009
Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.
Article in Cancer letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Deciphering the circadian signature in acute myeloid leukemia: NPAS2 downregulation as a master predictive feature.Blood research · 2026Article
- Circadian Gene NPAS2 Relieves Hypertrophic Scar Formation via CDC25A-Mediated Fibroblasts Activity.Journal of cellular and molecular medicine · 2025Article
- Article
- Effect ofFrontiers in endocrinology · 2022Article
- Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.American journal of cancer research · 2022Article
- Article
- Insights About Circadian Clock and Molecular Pathogenesis in Gliomas.Frontiers in oncology · 2020Review
- Dysregulated lncRNA-miRNA-mRNA Network Reveals Patient Survival-Associated Modules and RNA Binding Proteins in Invasive Breast Carcinoma.Frontiers in genetics · 2019Article
- Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression.Cancer cell international · 2019Article
- Article
- Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.International journal of cancer · 2017Article
- A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma.Experimental biology and medicine (Maywood, N.J.) · 2017Article
- Uncoupling genotoxic stress responses from circadian control increases susceptibility to mammary carcinogenesis.Oncotarget · 2017Article
- NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A.Cell death & disease · 2017Article
- Collaborator of alternative reading frame protein (CARF) regulates early processing of pre-ribosomal RNA by retaining XRN2 (5'-3' exoribonuclease) in the nucleoplasm.Nucleic acids research · 2015Article
- Electric light, particularly at night, disrupts human circadian rhythmicity: is that a problem?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- Discovery of prognostic biomarkers for predicting lung cancer metastasis using microarray and survival data.BMC bioinformatics · 2015Article
- Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients.Cancer science · 2014Article
- Circadian gene variants in cancer.Annals of medicine · 2014Review
- A novel autoantibody test for the detection of pre-neoplastic lung lesions.Molecular cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The transcription factor NPAS2 is one of nine human core circadian genes that influence a variety of biological processes by regulating the 24-h circadian rhythm. Recently, it has been shown that NPAS2 is a risk biomarker in human cancers and plays a role in tumorigenesis by affecting cancer-related gene expression, and relevant biological pathways. However, it is difficult to study the biological involvement of NPAS2 in cancer development, as little is known about its direct transcriptional targets. The aim of the current study is to create a transcriptional profile of genes regulated by NPAS2, using a human binding ChIP-on-chip analysis of NPAS2 in MCF-7 cells. This genome-wide mapping approach identified 26 genes that contain potential NPAS2 binding regions. Subsequent real-time PCR assays confirmed 16 of these targets, and 9 of these genes (ARHGAP29, CDC25A, CDKN2AIP, CX3CL1, ELF4, GNAL, KDELR1, POU4F2, and THRA) have a known role in tumorigenesis. In addition, a networking analysis of these validated NPAS2 targets revealed that all nine genes, together with REN, are involved in a "Cancer, Cell cycle, Neurological Disease" network. These results report the first list of direct transcriptional targets of NPAS2 and will shed light on the role of circadian genes in tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.